Narcolepsy's First Orexin Agonist Lands in Schedule IV, 99 Days After FDA Approval

Narcolepsy type 1 has its first drug aimed at the missing orexin signal, and as of Nov. 12, 2026, it has a federal schedule. The Drug Enforcement Administration placed oveporexton in schedule IV of the Controlled Substances Act through an interim final rule that took effect on publication.

Oveporexton, sold by Takeda as Orzeyful, is an oral orexin type 2 receptor agonist that the Food and Drug Administration approved on Aug. 5, 2026, for adults with narcolepsy type 1. Takeda said in its approval announcement that it would make the drug available after DEA scheduling, through a specialty pharmacy. That condition is now met, 99 days after approval.

Why schedule IV

The Department of Health and Human Services sent DEA its eight-factor analysis and a schedule IV recommendation on July 31, before approval. DEA agreed. In a human abuse potential study of 43 non-dependent recreational users with stimulant experience, oveporexton at 18 mg and 30 mg, far above the labeled dose, produced peak Drug Liking scores that were not statistically different from phentermine 75 mg, a schedule IV stimulant. Take Drug Again scores were also similar to phentermine's.

Other signals pointed lower. In rats, oveporexton did not substitute for d-amphetamine in drug discrimination testing, and only one of four doses was self-administered more than vehicle. Across six repeated-dose trials with 277 participants, HHS found no consistent withdrawal pattern. Potential abuse-related adverse events occurred in 19.4 percent of participants without narcolepsy who took 30 to 75 mg a day, and were infrequent in patients with narcolepsy type 1 at 4 mg a day or less.

DEA added one argument of its own. Citing a secondary analysis in JAMA Neurology of a 112-patient phase 2 trial, which found better attention, memory and executive function at eight weeks, DEA wrote that possible cognitive enhancement "may increase the attractiveness of the drug for diversion and abuse." The authors of that analysis had suggested the effect might reflect treatment of the underlying disease, and DEA notes that it has not been shown outside narcolepsy type 1.

How long did scheduling take?

Since a 2015 law, the Improving Regulatory Transparency for New Medical Therapies Act, DEA must issue an interim final rule within 90 days for a newly approved drug that HHS recommends controlling. The clock starts on the later of two dates: when DEA receives the HHS recommendation, or when it receives notice of FDA approval. The oveporexton rule does not say when DEA received the approval notice, so we measured every case the same way, from FDA approval to the rule's effective date, using the dates DEA reports in each rule.

The median across the 14 drugs is 90 days. Only lemborexant, cenobamate and lasmiditan took longer than oveporexton, and in each of those rules DEA reported receiving FDA's approval notice or the HHS evaluation weeks after approval. For lemborexant, a letter dated March 5, 2020, told DEA about a Dec. 20, 2019, approval. This year's two most recent cases, centanafadine at 98 days and oveporexton at 99, are the longest since lemborexant in April 2020 by this measure.

For a drug that cannot launch until it is scheduled, every day past approval is a day patients wait. This one waited a little longer than most.

What the label asks of prescribers

FDA based approval on two phase 3 trials, FirstLight and RadiantLight. Takeda's announcement lists insomnia, urinary frequency, urinary urgency and excess saliva as the most common adverse reactions. In pooled phase 3 data, insomnia occurred in 60 percent of patients on 2 mg twice daily, 55 percent on 1 mg twice daily and 1 percent on placebo; urinary frequency in 58, 53 and 5 percent. Creatine kinase above five times the upper limit of normal occurred in 11 percent of oveporexton patients (21 of 196) and 5 percent on placebo (4 of 76). Strong CYP3A inhibitors are contraindicated. The labeled dose is 1 or 2 mg on waking and again three to five hours later; DEA reports a mean half-life of 23.2 hours.

Schedule IV places oveporexton alongside solriamfetol among narcolepsy drugs and phentermine among stimulants. Prescriptions must meet DEA's prescription rules in 21 CFR part 1306, which for schedule IV allow up to five refills within six months, and prescribers need a DEA registration that covers schedule IV.

What to watch

DEA is taking comments and hearing requests on the interim rule until Dec. 14, 2026. Takeda has not said in the announcement we reviewed what the drug will cost. For sleep physicians the near-term work is practical: identify patients with confirmed narcolepsy type 1, screen for urinary symptoms and CYP3A interactions before starting, check creatine kinase if muscle symptoms appear, and expect specialty-pharmacy paperwork with the first prescriptions. The same day DEA scheduled oveporexton, it was also raising stimulant production quotas for the drugs many of these patients take now.

Share this storyImages sized for Facebook, Instagram, TikTok, X and link previews

Download all imagesCopy link

This article is for professional education and does not replace clinical judgment. Treatment decisions should be based on the individual patient and current guidelines.